Filing Details

Accession Number:
0001193125-20-004330
Form Type:
13G Filing
Publication Date:
2020-01-09 09:30:37
Filed By:
Vanderfelt William Weeks
Company:
Apyx Medical Corp (NASDAQ:APYX)
Filing Date:
2020-01-09
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
William Weeks Vanderfelt 3,158,414 0 3,158,414 0 3,158,414 9.2%
Filing

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

 

 

APYX MEDICAL CORPORATION

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

03837C106

(CUSIP Number)

December 31, 2019

(Date of Event which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

* 

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 03837C106    13G    Page 2 of 5 Pages

 

  1.    

   NAMES OF REPORTING PERSONS

 

  William Weeks Vanderfelt

  2.    

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

  (a)  ☐        (b)  ☒

 

  3.    

  SEC USE ONLY

 

  4.    

   CITIZENSHIP OR PLACE OF ORGANIZATION

 

   United Kingdom

NUMBER OF

SHARES

  BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH

    5.     

  SOLE VOTING POWER

 

  3,158,414

  6.     

  SHARED VOTING POWER

 

  0

  7.     

  SOLE DISPOSITIVE POWER

 

  3,158,414

  8.     

  SHARED DISPOSITIVE POWER

 

  0

9.    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  3,158,414

10.    

  CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

 

  ☐

11.    

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

  9.2% (1)

12.    

  TYPE OF REPORTING PERSON (see instructions)

 

  IN

 

(1)

The percentage set forth in Row 11 of this Cover Page is based on the 34,168,230 shares of Common Stock (as defined herein) of the Issuer (as defined herein) outstanding as of November 11, 2019, as reported in the Issuers Form 10-Q filed with the Securities and Exchange Commission on November 15, 2019.


CUSIP No. 03837C106    13G    Page 3 of 5 Pages

 

Item 1.

 

  (a)

Name of Issuer

Apyx Medical Corporation

 

  (b)

Address of Issuers principal executive offices

5115 Ulmerton Road, Clearwater, Florida 33760

Item 2.

 

  (a)

Name of person filing

This Schedule 13G is being filed on behalf of William Weeks Vanderfelt with respect to the shares of Common Stock, $0.001 par value per share (the Common Stock), of Apyx Medical Corporation, a Delaware corporation (the Issuer).

 

  (b)

Address or principal business office or, if none, residence

Chemin du Cli 13B, 1936 Verbier, Switzerland

 

  (c)

Citizenship

See Row 4 of the Cover Page.

 

  (d)

Title of class of securities

Common Stock, par value $0.001 per share

 

  (e)

CUSIP No.

03837C106

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a)

☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

  (b)

☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

  (c)

☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

  (d)

☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

  (e)

☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

  (f)

☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

  (g)

☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

  (h)

☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

  (i)

☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

  (j)

☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

 

  (k)

☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:


CUSIP No. 03837C106    13G    Page 4 of 5 Pages

 

Item 4. Ownership.

The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the Cover Page and is incorporated herein by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


CUSIP No. 03837C106    13G    Page 5 of 5 Pages

 

SIGNATURE

After reasonable inquiry and to the best of the undersigneds knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATED: January 9, 2020

 

By:  

/s/ WILLIAM WEEKS VANDERFELT

  William Weeks Vanderfelt